Clem Jones Centre for Regenerative Medicine, Bond University, Gold Coast, Queensland, 4229, Australia.
Stem Cell Res Ther. 2021 Apr 21;12(1):248. doi: 10.1186/s13287-021-02316-7.
Age-related macular degeneration (AMD) is a highly prevalent form of blindness caused by loss death of cells of the retinal pigment epithelium (RPE). Transplantation of pluripotent stem cell (PSC)-derived RPE cells is considered a promising therapy to regenerate cell function and vision.
The objective of this study is to develop a rapid directed differentiation method for production of RPE cells from PSC which is rapid, efficient, and fully defined and produces cells suitable for clinical use.
A protocol for cell growth and differentiation from hESCs was developed to induce differentiation through screening small molecules which regulated a primary stage of differentiation to the eyefield progenitor, and then, a subsequent set of molecules to drive differentiation to RPE cells. Methods for cell plating and maintenance have been optimized to give a homogeneous population of cells in a short 14-day period, followed by a procedure to support maturation of cell function.
We show here the efficient production of RPE cells from human embryonic stem cells (hESCs) using small molecules in a feeder-free system using xeno-free/defined medium. Flow cytometry at day 14 showed ~ 90% of cells expressed the RPE markers MITF and PMEL17. Temporal gene analysis confirmed differentiation through defined cell intermediates. Mature hESC-RPE cell monolayers exhibited key morphological, molecular, and functional characteristics of the endogenous RPE.
This study identifies a novel cell differentiation process for rapid and efficient production of retinal RPE cells directly from hESCs. The described protocol has utility for clinical-grade cell production for human therapy to treat AMD.
年龄相关性黄斑变性(AMD)是一种由视网膜色素上皮(RPE)细胞死亡引起的高发性失明形式。多能干细胞(PSC)衍生的 RPE 细胞移植被认为是一种有前途的治疗方法,可以再生细胞功能和视力。
本研究的目的是开发一种从 PSC 快速、高效、完全定义的定向分化方法生产 RPE 细胞,该方法产生的细胞适合临床应用。
开发了一种从 hESC 诱导细胞生长和分化的方案,通过筛选调节向眼原基初级分化的小分子,然后用一组后续分子诱导向 RPE 细胞分化。优化了细胞接种和维持方法,使细胞在 14 天的短时间内形成均匀的细胞群体,然后进行支持细胞功能成熟的程序。
我们在这里展示了使用无饲养层系统中的小分子在无动物源/定义培养基中从人胚胎干细胞(hESC)高效生产 RPE 细胞。第 14 天的流式细胞术显示约 90%的细胞表达 RPE 标志物 MITF 和 PMEL17。时程基因分析证实了通过定义的细胞中间产物进行分化。成熟的 hESC-RPE 细胞单层表现出内源性 RPE 的关键形态、分子和功能特征。
本研究确定了一种从 hESC 快速、高效生产视网膜 RPE 细胞的新型细胞分化过程。所描述的方案可用于临床级细胞生产,以治疗 AMD 等人类疾病。